Home > News > Arrowhead Subsidiary Successful in Small Animal Studies
April 20th, 2005
Arrowhead Subsidiary Successful in Small Animal Studies
Abstract:
Arrowhead Research Corporation announced today that its majority-owned subsidiary, Insert Therapeutics, has released data demonstrating effective anti-cancer results in animal studies of its lead product, IT-101, against various cancers, including pancreatic cancer, colon cancer, breast cancer, lung cancer, and Ewing's Sarcoma, a cancer primarily affecting children and young adults
Source:
businesswire
Bookmark:
| Related Links |
Arrowhead Research Corporation
| Related News Press |
Nanomedicine
Ben-Gurion University of the Negev researchers several steps closer to harnessing patient's own T-cells to fight off cancer June 6th, 2025
Cambridge chemists discover simple way to build bigger molecules – one carbon at a time June 6th, 2025
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Self-propelled protein-based nanomotors for enhanced cancer therapy by inducing ferroptosis June 6th, 2025
Announcements
Electrifying results shed light on graphene foam as a potential material for lab grown cartilage June 6th, 2025
Quantum computers simulate fundamental physics: shedding light on the building blocks of nature June 6th, 2025
A 1960s idea inspires NBI researchers to study hitherto inaccessible quantum states June 6th, 2025
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||